Emergent BioSolutions (EBS) EBIT Margin Growth (3y) (2014 - 2026)
Emergent BioSolutions (EBS) EBIT Margin Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 1,129.00 |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 2.00 |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 59.00 |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | -1,031.00 |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -925.00 |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | -46.00 |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6,666.00 |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 253.61 Mn | 112.71 Mn | 137.20 Mn | 3,329.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,329.00 |
| Mar 31, 2026 | 9,656.00 |
| Dec 31, 2025 | -202.00 |
| Sep 30, 2025 | 5,199.00 |
| Jun 30, 2025 | 3,259.00 |
| Mar 31, 2025 | 2,019.00 |
| Dec 31, 2024 | -4,401.00 |
| Sep 30, 2024 | 3,757.00 |
| Jun 30, 2024 | -40,888.00 |
| Mar 31, 2024 | -1,121.00 |
| Dec 31, 2023 | -6,011.00 |
| Sep 30, 2023 | -10,541.00 |
| Jun 30, 2023 | -11,861.00 |
| Mar 31, 2023 | -8,381.00 |
| Dec 31, 2022 | -3,833.00 |
| Sep 30, 2022 | -4,156.00 |
| Jun 30, 2022 | -2,857.00 |
| Mar 31, 2022 | 1,664.00 |
| Dec 31, 2021 | 3,499.00 |
| Sep 30, 2021 | -2,788.00 |